Previous 10 | Next 10 |
home / stock / trypf / trypf news
Atai Life Sciences (NASDAQ: ATAI) , a clinical-stage biopharmaceutical company whose objective is to transform how mental health conditions are treated, has increased its stake in Compass Pathways. Compass Pathways (NASDAQ: CMPS) is a mental health care company that is focused on improvin...
Pharmaceutical company Tryp Therapeutics is advancing research into the ability to treat unmet medical needs by using synthetic psychedelic drug candidates generally regarded as illegal and of no practical value under federal drug standards The company is demonstrating its faith in the ...
Eating disorders are severe mental and physical illnesses that encompass damaging relationships with body image, exercise, eating and food. Research has found that behaviors that are linked to eating disorders, such as fasting for weight loss, purging and binge eating, are almost as commo...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it will present at the Second Annual H.C. Wainwright Psychedelics Conference. The event is slated to be held v...
Tryp Therapeutics to Present at the H.C. Wainwright Psychedelics Conference on December 6, 2021 Canada NewsWire SAN DIEGO , Dec. 3, 2021 /CNW/ -- Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp or the "Company"), a pharmaceutical company focused on develo...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced its receipt of confirmation from the U.S. Food and Drug Administration (“FDA”) that its review of Try...
Tryp Therapeutics Receives Confirmation from FDA to Proceed with Phase 2a Study in Fibromyalgia Canada NewsWire SAN DIEGO , Dec. 2, 2021 /CNW/ -- Tryp Therapeutics (CSE:TRYP) (OTCQB:TRYPF) (" Tryp " or the " Company "), a pharmaceutical company focuse...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) recently submitted an Investigational New Drug (“IND”) application to the U.S. FDA to evaluate its TRP-8802 clinical candidate in a phase 2a clinical trial to explore psilocybin-assisted therapy’s safety and preliminary effe...
People with eating disorders know all about the difficulties faced during holiday celebrations and their association with heavy eating The fall-winter holiday season can also adversely affect people suffering from certain chronic pains, as temperatures and pressure changes can increase ...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is looking to transform the existing treatment of fibromyalgia, along with other forms of chronic pain, and relieve the suffering of millions of patients. To achieve this, the company is relying on the guidance of its scientific advisory board (...
News, Short Squeeze, Breakout and More Instantly...
Tryp Therapeutics Inc Com Company Name:
TRYPF Stock Symbol:
OTCMKTS Market:
Tryp Therapeutics Inc Com Website:
Kelowna, British Columbia--(Newsfile Corp. - May 17, 2024) - Tryp Therapeutics, Inc. (CSE: TRYP) (" Tryp " or the " Company ") announces, that it has filed amended financial statements for the six months ended February 29, 2024 (the " Financial Statements "), along with the corresponding Manage...
KELOWNA, BC / ACCESSWIRE / May 1, 2024 / Tryp Therapeutics, Inc. (" Tryp " or the " Company ") ( CSE:TRYP, OTCQB: TRYPF ) and Exopharm Limited ACN 163 765 991 (" Exopharm ") are pleased to announce that completion of the previously announced plan of arrangement (the " Arrangement ") effective ...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced that shareholders of Exopharm Limited ACN 163 765 991 approved...